Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 with or without Adebrelimab in Previously Treated Advanced Non-Squamous NSCLC
NCT07824882Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan, adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Started Oct 2026; status: recruiting.
02
Drugs
risvutatug rezetecanadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07824882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824882.